NEW YORK (GenomeWeb News) – Genomic cancer diagnostic services firm Kew Group today announced it has closed a private round of financing.

The Cambridge, Mass.-based firm did not disclose the amount of the round or how it will be used, and it did not respond to an e-mail seeking comment. However, in a document filed with the US Securities and Exchange Commission earlier this moth, Kew said that it raised $16.1 million toward a targeted goal of $30.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

Apr
15
Sponsored by
WaferGen

This live online seminar will highlight recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease.